First‐in‐Human, Healthy Volunteers Integrated Protocol of ETC‐206, an Oral Mnk 1/2 Kinase Inhibitor Oncology Drug

• Main Authors: Vincenzo Teneggi (Author), Veronica Novotny‐Diermayr (Author), Lay Hoon Lee (Author), Maryam Yasin (Author), Pauline Yeo (Author), Kantharaj Ethirajulu (Author), Sylvia Bong Hwa Gan (Author), Stephanie E. Blanchard (Author), Ranjani Nellore (Author), Dhananjay N. Umrani (Author), Roberto Gomeni (Author), Darren Lim Wan Teck (Author), Greg Li (Author), Qing Shu Lu (Author), Yang Cao (Author), Alex Matter (Author)
• Format: Book
• Published: Wiley, 2020-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

In the last decade, drug development has tackled substantial challenges to improve efficiency and facilitate access to innovative medicines. Integrated clinical protocols and the investigation of targeted oncology drugs in healthy volunteers (HVs) have emerged as modalities with an increase in scope...